• Charles River launched rapid cell banking programs targeting a 40% cut in cell bank production timelines versus the 20-week industry standard.
• Offering combines rapid pre-bank and release testing with Next-Generation Sequencing-based characterization using the iDTECT platform to support regulatory submissions.
• Rapid microbiological methods, including ATP-bioluminescence, replace compendial testing to speed microbial detection; real-time PCR shortens mycoplasma testing timelines.
• CGMP-compliant NGS services aim to accelerate development while meeting FDA and EMA expectations, including ICH Q5A and Q5B guidance.
• Pathoquest acquisition strengthens in vitro sequencing capabilities for characterization and quality control testing of biopharmaceutical products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609170800BIZWIRE_USPR_____20260916_BW131517) on September 17, 2026, and is solely responsible for the information contained therein.